v3.26.3
Business Segment and Geographic Information
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Business Segment and Geographic Information Business Segment and Geographic Information
Segment Reporting
Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, single-use insulin cartridges, and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as one reporting segment because key operating decisions and resource allocations are made by the CODM using consolidated financial data. Accordingly, the Company is organized as a single operating segment and therefore a single reportable segment: Insulin Pumps and Supplies.
The Company’s CODM is the Chief Executive Officer (CEO), who evaluates segment performance based on segment net income (loss) on a consolidated basis. Segment net income (loss) was consistent with the net loss amounts reported in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025. There were no significant segment expenses that are regularly provided to the CODM other than those reported in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025.
The Company’s CODM is provided segment assets information on a consolidated basis for the evaluation of Company performance. Total segment assets were consistent with total assets reported in the Company’s condensed consolidated balance sheets for September 30, 2026 and December 31, 2025.
Disaggregation of Sales
Segment revenues were consistent with revenue reported in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025. The Company primarily sells its products through national and regional distributors in the United States on a non-exclusive basis, and primarily through distribution partners internationally. In the United States, Canada, and select countries in Europe, the Company also uses a direct sales force. The Company disaggregates its revenue by geography, major sales channel, and product as management believes these categories best depict how the nature, amount, and timing of revenues and cash flows are affected by economic factors.
During the three and nine months ended September 30, 2026 and 2025, no individual country internationally generated revenue that represented more than 10% of total revenue. The table below sets forth revenues for the Company’s two primary geographical markets, based on the geographic location to which its products are shipped (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
United States$191,045 $175,631 $531,180 $496,472 
International92,645 73,622 254,291 227,881 
Total Sales$283,690 $249,253 $785,471 $724,353 
Sales within the pharmacy channel accounted for 15% and 5% of the Company’s United States sales for the three months ended September 30, 2026 and 2025, respectively. Sales within the pharmacy channel accounted for 10% and 3% of the Company’s United States sales for the nine months ended September 30, 2026 and 2025, respectively. Direct sales to customers accounted for 18% and 3% of the Company’s international sales for the three months ended September 30, 2026 and 2025, respectively. Direct sales to customers accounted for 14% and 4% of the Company’s international sales for the nine months ended September 30, 2026 and 2025, respectively.
During the three and nine months ended September 30, 2026 and 2025, sales by product were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Pump$114,956 $110,114 $340,034 $324,076 
Supplies and other168,734 139,139 445,437 400,277 
Total Sales$283,690 $249,253 $785,471 $724,353 
For the pay-as-you-go reimbursement model, the Company allocates a portion of the transaction price associated with the customer’s initial supply order to the pump based on its relative standalone selling price.